In summary, this integrated analysis provides the first clinical evidence that high-grade TNBC activates a coordinated tumor-systemic copper program characterized by elevated CTR1 expression and increased ΔCopper during neoadjuvant therapy. This evidence concerns the gene SLC31A1 and neoplasm.